N/A N=6 Study of the Ability of Betaine Hydrochloride to Increase Stomach Acid in Healthy Volunteers
Pharmacodynamic
Primary: Change in Gastric pH After Administration of Betaine Hydrochloride (HCl) — 4.54 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=76 Proteiomic Fingerprints of Gastric Juice
Gastric Cancer
Primary: Number of Participants With Accurate Diagnosis for Gastric Cancer — 27; 44 participants
Phase 4 N=39 Gastric Acid Suppression and Probiotic Colonization
Probiotics
Primary: Relative Abundance of VSL#3 Probiotic Bacterial Strains When Ingested in the Presence or Absence of the Proton Pump Inhibitor (PPI) Omeprazole at Week 4. — 1.002; 0.8186…
Phase 4 N=12 The Effect of Protein on Calcium Absorption and Gastric Acid Production
Osteoporosis
Primary: Percent Change in Intestinal Calcium Absorption — 34.2; 31.5 percentage of calcium absorption
N/A N=11 Gastric pH and Anthocyanin Absorption
Anthocyanin Metabolism
Primary: Gastric pH — 0.96; 2.31 pH
Phase 2 N=73 Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients
Indigestion
Primary: Percentage of Participants With Satisfactory Relief of Non-ulcer Dyspepsia Symptoms — 71; 34; 82; 56 percentage of participants
N/A N=126 Acetic Acid Chromoendoscopy to Judge Gastric Intestinal Metaplasia
Stomach Neoplasms · Metaplasia
Primary: Percent Agreement Between Acetic Acid Chromoendoscopy and Endoscopic Biopsy — 78.5; 94.4; 89.2; 67.1 percentage of lesions
N/A N=100 Gastric Ultrasound
Surgery
Primary: Aspiration Risk Grade — 30; 30; 20; 9 Participants
Phase 4 N=14 Effects of Gastric Acid on Colonic Microbiome
Clostridium Difficile
Primary: Shannon Diversity Index Measuring Change in Microbiome Diversity — 0.18; 0.14 Shannon index — p=0.71
Phase 3 N=63 Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)
Human Experimentation
Primary: Achievement of Sustained Difference in Inhibition of Intragastric Acidity Based on Median pH Values Between the Two Active Study Treatments at Steady-state on Day 7…
Phase 4 N=30 Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression
Normal Healthy Subject Population
Primary: The Mean Percent Time Gastric pH > 4.0 on Day 1
Phase 4 N=40 Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression
Healthy
Primary: Mean Percent Time That Gastric pH > 4.0 on Day 5 — 36.8; 45.7 percent time gastric pH exceeds 4.0 — p=< 0.0001
N/A N=1,490 Blood Tests for Gastritis and Gastric Neoplasms
Cancer Screening Tests
Primary: Significant Blood Test Findings Correlated With Gastric Neoplasms — 9.9; 6.5 score on a scale
Phase 1 N=105 Duration of Effect of Acidform Gel on Vaginal pH
Healthy
Primary: Change in Vaginal pH Following a Single Dose of Acidform (3, 4, and 5 g), HEC Placebo (4 g), or no Intervention. — 4.85; 4.81; 4.91; 5.00 pH
N/A N=449 Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation
Esophagogastroduodenoscopy · Colonoscopy
Primary: Residual Gastric Volumes of Different Bowel Preparation Regimens — 19; 16; 18 mL
N/A N=146 Aspiration of Residual Gastric Contents
Infant, Premature · Nutrition, Enteral
Primary: Enteral Intake on Day of Life 7 — 27.5; 22.6 mL/kg per day — p=0.27
Phase 4 N=40 Ulcer Prevention Study in Post Gastric Bypass Patients
Marginal Ulcers
Primary: Number of Participants With Complaints, Specifically About Pain, Vomiting, Dyspepsia, and/or Dysphagia. — 17; 13 participants
N/A N=60 Proton Pump Inhibitors and Dysbiosis in Cirrhosis
Cirrhosis · Healthy
Primary: Number of Patients With Overgrowth of Oral Microbiota in Their Stool After PPI Therapy Withdrawal or Initiation — 45; 15 Participants
Phase 4 N=301 Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer
Stomach Ulcer
Primary: Gastric Ulcer Healing Rate (Number of Subjects Whose Gastric Ulcer Was Healed/Number of Subjects Evaluated x 100) at Week 8 — 70.13; 60.54 percentage of participants
Phase 3 N=6 Effect on Bacterial Glycolytic Acid Formation on Plaque
Dental Plaque
Primary: ph of Dental Plaque After Sucrose Challenge — 4.88; 5.04; 4.98 ph of dental plaque — p=0.05
Phase 2 N=480 Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease
Primary: Change From Baseline in Percent Regurgitation-Free Days Over Weeks 5-8 — 36.96; 43.01; 44.37; 38.79 percentage of days — p=0.128
Phase 2 N=17 Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations
Cystic Fibrosis
Primary: Time to First Pulmonary Exacerbation — NA; NA Weeks
Phase 3 N=45 Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients
Gastroesophageal Reflux Disease
Primary: Percentage of Time During the 4-hour Post-dosing Period With pH Below pH 4 — 5.14; 14.94 percentage of time with pH below pH 4 — p=0.0003
Phase 4 N=87 Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole
Dyspepsia · Emergency · Pain
Primary: Pain Scores on the 100-millimeter Visual Analog Scale (VAS) at 1 Hour After Treatment — 17; 19 millimeter — p=0.6
N/A N=75 Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease
Gastro-esophageal Reflux Disease
Primary: TRPV1, GDNF, and NGF mRNA Expression of Esophageal Mucosa — 1.14; 3.25; 2.33; 1.39 Fold change
Phase 4 N=52 Role of Pepsin Assay in Wheezy Infants
Gastroesophageal Reflux Disease
Primary: Number of Participants in Each Level of Wheeze Control — 18; 11; 9 Participants
Phase 4 N=72 Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide
Pregnancy · Cesarean Section · Aspiration
Primary: Change in Gastric Volume (mL) — -1; -2; 0; 1 Milliliters — p=.001
Phase 3 N=50 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
Gastric Ulcer (GU) · Duodenal Ulcer (DU) · Anastomotic Ulcer (AU)
Primary: Disappearance of Heartburn at Week 8 by Patient Diaries — 2; 0; 0; 1 Participants
N/A N=61,864 Risk of Cancer Among Pantoprazole Users
Esophagitis
Primary: Incidence Rate of Gastric Cancer — 19.88; 23.73 incidence per 100000 person-years
Phase 4 N=19 Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
Primary: Gastric Emptying — 0.27; 0.384; 0.04; 0.051 percent meal retention — p=0.003